| 安晋婷,马梁明,王 涛,田卫伟,贺少龙.地西他滨联合小剂量HAG方案对急性髓系白血病患者细胞免疫功能及血清COX-2、bFGF的影响[J].,2021,(2):347-350 |
| 地西他滨联合小剂量HAG方案对急性髓系白血病患者细胞免疫功能及血清COX-2、bFGF的影响 |
| The Effect of Decitabine Combined with Low Dose HAG Scheme on the Cellular Immune Function and Serum COX-2 and bFGF in Patients with Acute Myeloid Leukemia |
| 投稿时间：2020-03-27 修订日期：2020-04-22 |
| DOI：10.13241/j.cnki.pmb.2021.02.032 |
| 中文关键词: 地西他滨 小剂量HAG方案 急性髓系白血病 细胞免疫 环氧合酶-2 碱性成纤维细胞生长因子 |
| 英文关键词: Decitabine Low dose HAG scheme Acute myeloid leukemia Cell immune Cyclooxygenase-2 Basic fibroblast growth factor |
| 基金项目:山西省科技厅软科学项目（2015041046） |
|
| 摘要点击次数: 830 |
| 全文下载次数: 610 |
| 中文摘要: |
| 摘要 目的：探讨地西他滨联合小剂量高三尖杉酯碱+阿糖胞苷+重组人粒细胞集落刺激因子(HAG)方案对急性髓系白血病（AML）患者细胞免疫功能及血清环氧合酶-2（COX-2）、碱性成纤维细胞生长因子（bFGF）的影响。方法：选取2016年4月~2019年4月期间山西白求恩医院收治的AML患者93例，根据随机数字表法分为对照组（n=46，HAG方案）和研究组（n=47，地西他滨联合小剂量HAG方案），比较两组患者临床疗效、细胞免疫功能、血清COX-2、bFGF水平的变化情况，记录两组治疗期间不良反应情况。结果：研究组治疗后的临床总有效率为80.85%（38/47），高于对照组的56.52%（26/46）（P<0.05）。两组治疗后CD3+、CD4+/CD8+、CD4+水平均下降，但研究组高于对照组（P<0.05）；两组患者CD8+水平均升高，且研究组高于对照组（P<0.05）。两组治疗后血清COX-2、bFGF水平均下降，且研究组低于对照组（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。结论：地西他滨联合小剂量HAG方案治疗可减轻AML患者机体免疫抑制，改善血清COX-2、bFGF水平，且用药安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of decitabine combined with low dose homoharringtonine and cytarabine and recombinant human granulocyte colony stimulating factor (HAG) scheme on the cellular immune function, serum cyclooxygenase-2 (COX-2) and basic fibroblast growth factor (bFGF) in patients with acute myeloid leukemia (AML). Methods: 93 patients with AML in Shanxi Bethune hospital from April 2016 to April 2019 were selected, they were divided into control group (n=46, HAG scheme) and study group (n=47, decitabine combined with low dose HAG scheme) according to the method of random number table. The changes of clinical efficacy, cellular immunity, serum COX-2, bFGF levels of the two groups were compared, and adverse reactions during treatment were recorded in the two groups. Results: The total clinical effective rate of the study group was 80.85% (38/47), which was higher than 56.52% (26/46) of the control group (P<0.05). After treatment, the levels of CD3+, CD4+/CD8+, and CD4+ in the two groups decreased, but those in the study group were higher than those in the control group (P<0.05). The level of CD8+ in the two groups increased, and that in the study group was higher than that in the control group (P<0.05). After treatment, the levels of serum COX-2 and bFGF in the two groups decreased, and those in the study group were lower than those in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The treatment of dexithabine combined with low dose HAG scheme can reduce the immunosuppression of AML patients, improve the levels of serum COX-2 and bFGF, and the drug safety is good. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
